Tuesday, July 22, 2014

Tuesday Features

XTL hopes to begin major lupus trial next year

XTL hopes to begin major lupus trial next year

XTL Biopharmaceuticals (NASDAQ:XTLB; TASE:XTL) is aiming to begin a Phase 2b clinical trial in the first half of 2015 with its hCDR1 peptide to treat patients with systemic lupus erythematosus (SLE). Josh Levine “We are in the process of finalizing our trial design, approaching the FDA and hope to have feedback from the agency before the end of this... [Read more of this feature]


Taking a ride across the BBB with biOasis

Taking a ride across the BBB with biOasis

biOasis (OTCQX:BIOAF; TSX-V:BTI) believes its Transcend family of technologies holds the key to allow drug therapies to penetrate the blood-brain barrier (BBB) – long considered a Holy Grail of neurological medical research – to treat diseases of the central nervous system. Rob Hutchison “Our Transcend breakthrough is a naturally occurring... [Read more of this feature]


Medifocus readies marketing expansion of Prolieve

Medifocus readies marketing expansion of Prolieve

Medifocus (OTCQX:MDFZF; TSX-V:MFS) is raising $6-million to $10-million to expand the sales and marketing of its minimally invasive Prolieve device as a treatment for benign prostatic hyperplasia (BPH), or enlarged prostate, and to expand its use to include the treatment of prostatitis and prostate cancer. Augustine Cheung “Our current marketing plan... [Read more of this feature]


More Posts From Tuesday Features

Briefs

WB starts Imprivata at outperform

WB starts Imprivata at outperform

William Blair has initiated coverage of Imprivata (NYSE:IMPR) with an “outperform” rating and an “aggressive growth” profile. The stock closed at $16.01 on Friday. “Although Imprivata targets a unique niche in the healthcare information technology space, its total addressable market is quite substantial,” writes analyst Ryan Daniels. “We... [Read more of this brief]


Avivagen to test dietary fish supplement in Thailand

Avivagen to test dietary fish supplement in Thailand

Avivagen (TSX-V:VIV) has entered an agreement with Nam Sai Farms of Thailand to conduct a trial to determine the effects of its OxC-beta on the grow-out parameters of tilapia. The trial will test the effects of two different levels of OxC-beta and a positive control product against a negative control on the grow-out parameters of tilapia raised in cages... [Read more of this brief]


Cynapsus to start Phase 2 trial of APL-130277


Cynapsus to start Phase 2 trial of APL-130277


Following communication from the FDA, Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH) announced that it will begin Phase 2 clinical studies for APL-130277 immediately. The CTH-105 study will be initiated according to a proposal submitted to the FDA under the company’s IND application. APL-130277 is an easy-to-administer, fast-acting reformulation... [Read more of this brief]


Venaxis responding to FDA questions on APPY1 Test

Venaxis responding to FDA questions on APPY1 Test

The FDA has reviewed Venaxis’ (NASDAQ:APPY) submission to market its APPY1 Test and has provided the company with questions and information requests about the submission. The CE Marked APPY1Test is a multi-analyte assay for aiding in identifying children, adolescent and young adult patients that are at low risk for appendicitis. Venaxis is compiling... [Read more of this brief]


Cantor starts Radius Health at buy

Cantor starts Radius Health at buy

Cantor Fitzgerald has initiated coverage of Radius Health (NASDAQ:RDUS) with a “buy” rating and $20 price target. The stock closed at $13.05 on Wednesday. “We like the simplicity of the company’s value proposition: a late-stage asset with near-term revenue potential, with the potential to cannibalize a $1-billion product in a market with... [Read more of this brief]


More Posts From Briefs
Email Newsletters with Constant Contact
Google+